Over the past 12 months, 0 insiders at Paratek Pharmaceuticals, Inc. filed 0 open-market SEC Form 4 transactions on PRTK: 0 purchases worth $0 and 0 sales worth $0. Insiders have been mixed over this period. The most recent filing was on .
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 9, 23 | Michael BighamExec. Chairman of the Board | SELL | 31.3K | $2.20 | $69K |
| Aug 9, 23 | Randall B. BrennerChief Development & Regulatory | SELL | 27.6K | $2.20 | $61K |
| Aug 9, 23 | William M. HaskelCLO, General Counsel & Sec. | SELL | 34.5K | $2.20 | $76K |
| Aug 9, 23 | Evan LohCEO | SELL | 49.0K | $2.20 | $108K |
| Mar 23, 23 | James D DonderoTenPercentOwner | BUY | 100.0K | $1.73 | $173K |
| Mar 22, 23 | James D DonderoTenPercentOwner | BUY | 106.0K | $1.77 | $188K |
| Mar 21, 23 | James D DonderoTenPercentOwner | BUY | 242.5K | $1.74 | $422K |
| Mar 20, 23 | James D DonderoTenPercentOwner | BUY | 105.1K | $1.40 | $147K |
| Mar 17, 23 | James D DonderoTenPercentOwner | BUY | 234.9K | $1.50 | $352K |
| Feb 21, 23 | Timothy R FransonDirector | SELL | 7.0K | $1.88 | $13K |
| Feb 21, 23 | Jeffrey SteinDirector | SELL | 7.0K | $1.90 | $13K |
| Dec 21, 22 | Michael BighamExec. Chairman of the Board | SELL | 15.8K | $1.99 | $31K |
| Dec 21, 22 | Randall B. BrennerChief Development & Regulatory | SELL | 4.5K | $1.99 | $9K |
| Dec 21, 22 | William M. HaskelCLO, General Counsel & Sec. | SELL | 7.0K | $1.99 | $14K |
| Dec 21, 22 | Evan LohCEO | SELL | 23.5K | $1.99 | $47K |
| Dec 21, 22 | Adam WoodrowPresident & Chief Commercial | SELL | 6.8K | $1.99 | $13K |
| Dec 13, 22 | Michael BighamExec. Chairman of the Board | SELL | 31.9K | $1.96 | $63K |
| Dec 13, 22 | Randall B. BrennerChief Development & Regulatory | SELL | 18.2K | $1.96 | $36K |
| Dec 13, 22 | William M. HaskelCLO, General Counsel & Sec. | SELL | 23.6K | $1.96 | $46K |
| Dec 13, 22 | Evan LohCEO | SELL | 61.9K | $1.96 | $121K |
| Dec 13, 22 | Adam WoodrowPresident & Chief Commercial | SELL | 6.3K | $1.96 | $12K |
| Dec 12, 22 | Michael BighamExec. Chairman of the Board | SELL | 19.5K | $1.98 | $39K |
| Dec 12, 22 | Randall B. BrennerChief Development & Regulatory | SELL | 11.1K | $1.98 | $22K |
| Dec 12, 22 | William M. HaskelCLO, General Counsel & Sec. | SELL | 14.4K | $1.98 | $29K |
| Dec 12, 22 | Evan LohCEO | SELL | 37.8K | $1.98 | $75K |
| Dec 12, 22 | Adam WoodrowPresident & Chief Commercial | SELL | 3.8K | $1.98 | $8K |
| Oct 28, 22 | Michael BighamExec. Chairman of the Board | SELL | 6.0K | $3.47 | $21K |
| Oct 28, 22 | Randall B. BrennerChief Development & Regulatory | SELL | 3.5K | $3.47 | $12K |
| Oct 28, 22 | William M. HaskelCLO, General Counsel & Sec. | SELL | 4.4K | $3.47 | $15K |
| Oct 28, 22 | Evan LohCEO | SELL | 8.8K | $3.47 | $31K |
| Oct 28, 22 | Adam WoodrowPresident & Chief Commercial | SELL | 4.6K | $3.47 | $16K |
| Aug 9, 22 | Michael BighamExec. Chairman of the Board | SELL | 28.6K | $2.66 | $76K |
| Aug 9, 22 | Randall B. BrennerChief Development & Regulatory | SELL | 19.6K | $2.66 | $52K |
| Aug 9, 22 | William M. HaskelCLO, General Counsel & Sec. | SELL | 22.5K | $2.66 | $60K |
| Aug 9, 22 | Evan LohCEO | SELL | 44.5K | $2.66 | $118K |
| Dec 15, 21 | Michael BighamExec. Chairman of the Board | SELL | 17.8K | $4.27 | $76K |
| Dec 15, 21 | Randall B. BrennerChief Development & Regulatory | SELL | 15.8K | $4.27 | $67K |
| Dec 15, 21 | William M. HaskelCLO, General Counsel & Sec. | SELL | 17.2K | $4.27 | $73K |
| Dec 15, 21 | Evan LohCEO | SELL | 49.3K | $4.27 | $210K |
| Dec 15, 21 | Adam WoodrowPresident & Chief Commercial | SELL | 22.6K | $4.27 | $97K |
| Dec 14, 21 | Michael BighamExec. Chairman of the Board | SELL | 8.6K | $4.37 | $38K |
| Dec 14, 21 | Randall B. BrennerChief Development & Regulatory | SELL | 7.6K | $4.37 | $33K |
| Dec 14, 21 | William M. HaskelCLO, General Counsel & Sec. | SELL | 8.3K | $4.37 | $36K |
| Dec 14, 21 | Evan LohCEO | SELL | 23.8K | $4.37 | $104K |
| Dec 14, 21 | Adam WoodrowPresident & Chief Commercial | SELL | 10.9K | $4.37 | $48K |
| Dec 13, 21 | Michael BighamExec. Chairman of the Board | SELL | 5.1K | $4.42 | $22K |
| Dec 13, 21 | Randall B. BrennerChief Development & Regulatory | SELL | 4.5K | $4.42 | $20K |
| Dec 13, 21 | William M. HaskelCLO, General Counsel & Sec. | SELL | 4.9K | $4.42 | $22K |
| Dec 13, 21 | Evan LohCEO | SELL | 14.0K | $4.42 | $62K |
| Dec 13, 21 | Adam WoodrowPresident & Chief Commercial | SELL | 6.4K | $4.42 | $28K |
Over the past 12 months, insiders at Paratek Pharmaceuticals, Inc. filed 0 open-market purchases worth $0 and 0 sales worth $0 on PRTK, which makes them mixed over the period. The most recent Form 4 was filed on .
The largest recent open-market PRTK insider purchase in our data was $422K by James D Dondero, TenPercentOwner, filed on Mar 21, 23.
0 different insiders at Paratek Pharmaceuticals, Inc. filed open-market SEC Form 4 transactions on PRTK over the last 12 months.
InsiderTape plots every PRTK insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Paratek Pharmaceuticals, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →